Better Therapeutics Stock Short Ratio
Better Therapeutics fundamentals help investors to digest information that contributes to Better Therapeutics' financial success or failures. It also enables traders to predict the movement of Better OTC Stock. The fundamental analysis module provides a way to measure Better Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Better Therapeutics otc stock.
Better |
Better Therapeutics OTC Stock Short Ratio Analysis
Better Therapeutics' Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Current Better Therapeutics Short Ratio | 0.94 X |
Most of Better Therapeutics' fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Better Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
CompetitionBased on the latest financial disclosure, Better Therapeutics has a Short Ratio of 0.94 times. This is 75.9% lower than that of the Biotechnology sector and 87.31% lower than that of the Health Care industry. The short ratio for all United States stocks is 76.5% higher than that of the company.
Better Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Better Therapeutics' direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Better Therapeutics could also be used in its relative valuation, which is a method of valuing Better Therapeutics by comparing valuation metrics of similar companies.Better Therapeutics is currently under evaluation in short ratio category among its peers.
Better Fundamentals
| Return On Equity | -10.22 | |||
| Return On Asset | -0.95 | |||
| Current Valuation | 8.83 M | |||
| Shares Outstanding | 54.52 M | |||
| Shares Owned By Insiders | 53.41 % | |||
| Shares Owned By Institutions | 2.94 % | |||
| Number Of Shares Shorted | 2.13 M | |||
| Price To Book | 2.29 X | |||
| Price To Sales | 49,559 X | |||
| Gross Profit | (674 K) | |||
| EBITDA | (29.18 M) | |||
| Net Income | (31.57 M) | |||
| Cash And Equivalents | 29.68 M | |||
| Cash Per Share | 1.25 X | |||
| Total Debt | 14.88 M | |||
| Debt To Equity | 0.81 % | |||
| Current Ratio | 5.23 X | |||
| Book Value Per Share | (0.24) X | |||
| Cash Flow From Operations | (26.08 M) | |||
| Short Ratio | 0.94 X | |||
| Earnings Per Share | (1.10) X | |||
| Target Price | 5.25 | |||
| Number Of Employees | 54 | |||
| Beta | 2.35 | |||
| Market Capitalization | 1.12 M | |||
| Total Asset | 22.94 M | |||
| Retained Earnings | (111.5 M) | |||
| Working Capital | 4.95 M | |||
| Z Score | -10.7 | |||
| Net Asset | 22.94 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Consideration for investing in Better OTC Stock
If you are still planning to invest in Better Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Better Therapeutics' history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |